Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 32979
â€œNO Gasâ€ means nitric oxide gas.
â€œNO Gas Containerâ€ means a storage vessel for NO Gas.
â€œNO Gas Delivery Device(s)â€ means devices used for the delivery of NO Gas that contain Intellectual Property Licensed by CareFusion to Licensee.
Nitric Oxide (NO) possesses broad-spectrum anti-microbial activity acting against bacteria, fungi and viruses. NO is produced at high output as part of the innate immune response. NO and its by-products (for example, Reactive Nitrogen Species, RNS) are responsible for the process of killing microorganisms within white blood cells called macrophages and in organs such as the lungs and other mucolytic tissues.
IPSCIO Record ID: 228775
IPSCIO Record ID: 256986
GeNOvent is a cylinder free, phasic flow nitric oxide delivery system and has been designated as a medical device by the US Food and Drug Administration (FDA). The device can generate NO on demand for delivery to the lungs at concentrations ranging from 1 part per million (ppm) to 80 ppm. A disposable smart filter is used to remove nitrogen dioxide (NO2), a toxic gas. The elimination of the need for large, high-pressure cylinders for NO is a significant advantage in the hospital setting by greatly reducing inventory and storage requirements, and improving overall safety with the elimination of NO2 purging steps, among other benefits.
The Licensor is a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension.
Nitric oxide (NO) is a crucially important molecule proven to play a critical role in a broad array of biological functions. Inhaled nitric oxide is currently approved for treating term and near-term neonates with Persistent Pulmonary Hypertension of the Newborn (PPHN) in the United States of America and most major markets. In Europe, Japan and Australia, inhaled NO is approved to treat PPHN as well as pulmonary hypertension during the peri-operative cardiac surgery period in neonates, children, and adults. In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm. In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate their multi-drug resistant strains.
Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4â€“6.8/1000 live births) with mortality rate ranging between 4â€“33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a pulmonary vasodilator and is approved in dozens of countries to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents.
IPSCIO Record ID: 28731
Licensor hereby further grants the right to sublicense the Licenses granted herein.
What is required is a nitric oxide generator which is capable of producing nitric oxide and diluting the pure nitric oxide into concentrations that have utility.
Presently nitric oxide is successfully being used with FDA approval in the treatment of newborns with respiratory illness. Ongoing medical research shows promise in the use of NO for the treatment of a myriad of diseases and illnesses partially due to its antiviral and bactericidal properties.
IPSCIO Record ID: 248285
6,715,485 – Nasal delivery device
8,327,844 – Nasal delivery method
7,740,014 – Nasal devices
Product(s) means any products or product candidates developed by or under the authority of a Party or any of its Affiliates as of the Effective Date or during the Term consisting of a formulation that contains [as its sole active ingredient] a compound within the class of compounds [known as triptans], including any salt, polymorphic or amorphous form of such a compound, that is delivered in a nasal delivery device; [provided that, the foregoing definition of Product may be amended and expanded by the mutual agreement of the Parties, in each Partys sole discretion, to include a formulation of triptan with one or more other active ingredients]. For purposes of the foregoing, the class of compounds known as [triptans] includes the compounds known as of the Effective Date as the following Sumatriptan[, rizatriptan, naratriptan, zolmitriptan, almotriptan, frovatriptan, avitriptan and eletriptan]. Solely for the purposes of a Product shall also include products or product candidates consisting of [ a formulation that contains a compound within the class of compounds known as triptans (including any salt, polymorphic or amorphous form of such a compound) together with one or more other active ingredients, that is delivered in a nasal delivery device].
Licensor Trademarks means, any, whether domestic or foreign, trademarks, service marks, and trade names Controlled by Licensor or any of its Affiliates as of the Effective Date or during the Term that are used (or required to be used) in connection with the Device or a Product in the Licensed Territory, including those trademarks, service marks and trade names listed (the 'Existing Licensor Trademarks').
Service marks and trade names
Optimist, Optimose, Breath Powered, Bi-Directional
IPSCIO Record ID: 243410
For the Commercialization Licenses, Licensor grants to Licensee
– an exclusive right and license in the Territory, with the right to grant sublicenses, under Licensors rights in Licensor Intellectual Property and Joint Intellectual Property, to make, use, sell, offer to sell and import Royalty-Bearing Products incorporating Licensor Delivered Compounds; and
– a non-exclusive right and license in the Territory, with the right to grant sublicenses, under Licensors rights in the Licensors Intellectual Property other than the Licensor Composition Patent Rights, to make, use, sell, offer to sell and import Royalty-Bearing Products incorporating Limited License Compounds.
Product shall mean a medical device or a specialty catheter product developed for use in the Field, in either case incorporating one or more Licensor Nitric Oxide Releasing Compounds. Nitric Oxide Releasing Compounds shall mean compounds that donate, release and/or directly or indirectly transfer nitrogen monoxide, such that the biological activity of the nitrogen monoxide is expressed at an intended site of action.
Product relates to stents coated with nitric oxide-releasing compounds.
This development and license agreement is for the research, development and commercialization of cardiovascular stents coated with nitric oxide-enhancing medicines. Stents, or wire mesh devices, are typically inserted into narrowed coronary arteries to maintain blood flow.